Clinical Trials Logo

Clinical Trial Summary

This study conducted a prospective, multicenter, one-arm clinical trial on the combination of leflunomide and steroid therapy for refractory skin Henoch-Schonlein Purpura in children on the basis of ethical principles. A one-year follow-up was conducted to evaluate the changes in the main indicators (frequency of rash recurrence) and secondary indicators (proportion of kidney damage, proportion of joint involvement, T lymphocyte subpopulations, and inflammatory factors) before and after treatment, Exploring the safety and effectiveness of leflunomide in the treatment of refractory skin type HSP in children, it is expected that leflunomide combined with conventional treatment can improve the remission rate of HSP children's skin purpura and reduce HSP recurrence. The research results are expected to bring new treatment methods and strategies for this group of patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05937880
Study type Interventional
Source Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Haiyan Wang, MD
Phone +8613560489257
Email wanghy78@mail.sysu.edu.cn
Status Recruiting
Phase N/A
Start date January 1, 2023
Completion date June 30, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT02967068 - VCRC Tissue Repository